ICUD-EAU international consultation on kidney cancer 2010: Treatment of metastatic disease

European Urology

Volumn 60, Issue 4, 2011, Pages 684-690

  Patard, Jean Jacques ^a   Pignot, Geraldine ^b   Escudier, Bernard ^c   Eisen, Tim ^d   Bex, Axel ^e   Sternberg, Cora ^f   Rini, Brian ^g   Roigas, Jan ^h   Choueiri, Toni ⁱ   Bukowski, Ronald ^g   Motzer, Robert ^j   Kirkali, Ziya ^k   Mulders, Peter ^l   Bellmunt, Joaquim ^m  

^a BICÊTRE HOSPITAL   (France)

^b Institut Cochin   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g TAUSSIG CANCER INSTITUTE   (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k DOKUZ EYLUL UNIVERSITY   (Turkey)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m HOSPITAL DEL MAR   (Spain)

more..

Author keywords

First line; mTOR inhibitors; Renal cell carcinoma; Second line; Treatment algorithms; VEGF targeted therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AXITINIB; BEVACIZUMAB; CREATININE; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; COMPETITIVE INHIBITION; CONSENSUS; CONSULTATION; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDICAL LITERATURE; MEDLINE; METASTASECTOMY; METASTASIS; METASTATIC RENAL CELL CARCINOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; METASTASECTOMY; NEPHRECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80052263465     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.017     Document Type: Review

References (50)

1. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle Estimates of the caner incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592 (Pubitemid 46359643)
2. B.I. Rini, S.C. Campbell, and B. Escudier Renal cell carcinoma Lancet 373 2009 1119 1132
3. J.C. Yang, R.M. Sherry, and S.M. Steinberg Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 2003 3127 3132 (Pubitemid 46606294)
4. C. Coppin, F. Porzsolt, A. Awa, J. Kumpf, A. Coldman, and T. Wilt Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev 2005 CD001425
5. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540 (Pubitemid 29368255)
6. W.K. Rathmell, T.M. Wright, and B.I. Rini Molecularly targeted therapy in renal cell carcinoma Expert Rev Anticancer Ther 5 2005 1031 1040 (Pubitemid 43033793)
7. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296 (Pubitemid 34032623)
8. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
9. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
10. B. Ljungberg, N.C. Cowan, and D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
11. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2008 2103 2111
12. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
13. B.J. Escudier, J. Bellmunt, and S. Negrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
14. B.I. Rini, S. Halabi, and J. Rosenberg Phase III trial bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
15. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
16. Sternberg CN, Hawkins RE, Szczylik C, et al. Randomized, double-blind phase III study of pazopanib in patients with advanced metastatic renal cell carcinoma (MRCC): final overall survival (OS) results. Presented at: ESMO Congress; October 8-12, 2010; Milan, Italy; Abstract LBA22.
17. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
18. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
19. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
20. R.J. Motzer, B.I. Rini, and R.M. Bukowski Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524 (Pubitemid 43854967)
21. R.J. Motzer, M.D. Michaelson, and B.G. Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24 (Pubitemid 46630489)
22. M.P. Sablin, S. Negrier, and A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34 discussion 34
23. B.I. Rini, M.D. Michaelson, and J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748
24. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
25. B. Escudier, M. Gross Goupil, C. Massard, and K. Fizazi Sequential therapy in renal cell carcinoma Cancer 115 2009 2321 2326
26. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
27. R.J. Motzer, B. Escudier, and S. Oudard Phase III trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
28. J. Sosman, and I. Puzanov Combination targeted therapy in advanced renal cell carcinoma Cancer 115 2009 2368 2375
29. D.R. Feldman, M.S. Baum, and M.S. Ginsberg Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1432 1439
30. N.S. Azad, E.M. Posadas, and V.E. Kwitkowski Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J Clin Oncol 26 2008 3709 3714
31. J.A. Gollob, W.K. Rathmell, and T.M. Richmond Phase II Trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 2007 3288 3295 (Pubitemid 47325614)
32. B.I. Rini Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma? Nat Clin Pract Urol 5 2008 132 133 (Pubitemid 351377143)
33. B. Escudier, S. Negrier, and G. Gravis Can combination of temsirolimus and bevacizumab improve the treatment of metastatic renal carcinoma? Results of the randomized TORAVA phase II trial [abstract] J Clin Oncol 28 Suppl 2010 4516
34. A. Patnaik, A. Ricart, and J. Cooper A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract] J Clin Oncol 25 Suppl 2007 3512
35. J.D. Hainsworth, D.R. Spigel, H.A. Burris 3rd, D. Waterhouse, B.L. Clark, and R. Whorf Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2010 2131 2136
36. G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970 (Pubitemid 32913522)
37. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659 (Pubitemid 33126820)
38. A.A. Van der Veldt, M.R. Meijerink, and A.J. van den Eertwegh Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 14 2008 2431 2436 (Pubitemid 351551077)
39. V. Margulis, and C.G. Wood Pre-surgical targeted molecular therapy in renal cell carcinoma BJU Int 103 2009 150 153
40. A.A. Thomas, B.I. Rini, and B.R. Lane Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 181 2009 518 523 discussion 523
41. L. Wood, J.A. Garcia, and P. Elson Sunitinib in patients with unresectable primary renal cell carcinoma (RCC) [abstract] J Clin Oncol 27 Suppl 2009 5096
42. E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 4076 4081
43. T. Logan, D.F. McDermott, and J.P. Dutcher Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features [abstract] J Clin Oncol 26 Suppl 2008 5050
44. E.J. Abel, and C.G. Wood Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy Nat Rev Urol 6 2009 375 383
45. P. Russo Multi-modal treatment for metastatic renal cancer: the role of surgery World J Urol 28 2010 295 301
46. J.P. Kavolius, D.P. Mastorakos, C. Pavlovich, P. Russo, M.E. Burt, and M.S. Brady Resection of metastatic renal cell carcinoma J Clin Oncol 16 1998 2261 2266 (Pubitemid 28265066)
47. S. Piltz, G. Meimarakis, M.W. Wichmann, R. Hatz, F.W. Schildberg, and H. Fuerst Long-term results after pulmonary resection of renal cell carcinoma metastases Ann Thorac Surg 73 2002 1082 1087 (Pubitemid 34275883)
48. J. Pfannschmidt, H. Hoffmann, T. Muley, S. Krysa, C. Trainer, and H. Dienemann Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma Ann Thorac Surg 74 2002 1653 1657 (Pubitemid 35222660)
49. J.A. Karam, B.I. Rini, and L. Varella Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma J Urol 185 2011 439 444
50. A. Bex, E. Jonasch, and Z. Kirkali Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials Eur Urol 58 2010 819 828